Printer Friendly

ABBOTT AGREES TO SELL STAKE IN BOSTON SCIENTIFIC

 ABBOTT AGREES TO SELL STAKE IN BOSTON SCIENTIFIC
 ABBOTT PARK, Ill., April 3 /PRNewswire/ -- Abbott Laboratories


(NYSE: ABT) has entered into a contract to sell its 20 percent holding in Boston Scientific Corp. to that corporation in conjunction with and contingent upon, completion of Boston Scientific's contemplated initial public offering.
 Boston Scientific filed a registration statement today with the Securities and Exchange Commission. The registration statement says it is currently estimated that the initial public offering price will be $19-$22 per share.
 There is no guarantee that the shares offered will be sold, when they will be sold and if sold, that the range of prices will be realized. However, if the offering is successfully completed within that range, Abbott would receive a net price per share equal to that achieved in the public offering and realize an after-tax gain in the range of $185 million to $220 million. The transaction, if completed, is not expected to occur prior to May 1992.
 Abbott Laboratories is a worldwide manufacturer of health care products employing some 46,000 people. In 1991, the company's sales and net earnings were $6.9 billion and $1.1 billion, respectively, with earnings per share of $2.55.
 -0- 4/3/92
 /CONTACT: Cathy Babington of Abbott Laboratories, 708-937-3931/
 (ABT) CO: Abbott Laboratories; Boston Scientific Corp. ST: Illinois, Massachusetts IN: MTC SU:


CK -- NY083 -- 5091 04/03/92 18:40 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 3, 1992
Words:235
Previous Article:OCE-OFFICE SYSTEMS FILES DECLARATORY JUDGMENT ACTION AGAINST EASTMAN KODAK
Next Article:THE HUMAN SIDE OF LANSING'S POLITICAL FIGHT


Related Articles
ABBOTT TO PURCHASE FOUR MILLION SHARES
ABBOTT CONFIRMS INTENT TO DIVEST STAKE IN BOSTON SCIENTIFIC
Biocompatibles International plc - ABBOTT TO ACQUIRE GUIDANT VASCULAR BUSINESS.
Abbott Announces Amendment to Agreement With Boston Scientific to Acquire Guidant's Vascular Business.
Boston Scientific Files Notification with European Commission.
Boston Scientific Receives FTC Antitrust Approval for its Combination with Guidant.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters